中国卒中临床研究中的溶栓治疗：20年的成就与发展方向

doi:10.3969/j.issn.1673-5765.2025.05.003

摘要/Abstract

摘要： 2002年，《急性脑梗死六小时以内的静脉溶栓治疗》多中心尿激酶RCT结果的发表，标志着中国缺血性卒中溶栓药物研究的开始。此后，中国脑血管病领域工作者学习国际先进经验，遵循国际指南的指导，不断规范和完善我国缺血性卒中的溶栓治疗。20年后的今天，我国已能独立开展创新研发，新型溶栓药物的不断推出、治疗时间窗的不断突破、联合治疗方案的不断创新，使中国的卒中溶栓研究站到了世界舞台中央。本文以亲历者的视角，回顾近20年来中国缺血性卒中临床研究中溶栓治疗的变革历程。

关键词: 中国; 溶栓治疗; 急性缺血性卒中

Abstract: In 2002, the results of multicenter RCT of Intravenous Thrombolysis with Urokinase for Acute Cerebral Infarctions were published, marking the beginning of research on thrombolytic drugs for ischemic stroke in China. Subsequently, Chinese researchers in the field of cerebrovascular disease have cautiously learned from international advanced experience, followed the guidance of international guidelines, and continuously standardized and improved thrombolytic therapy for ischemic stroke in China. Today, two decades later, China is capable of independently carrying out innovative research and development. The continuous introduction of new thrombolytic drugs, the continuous breakthroughs in treatment time windows, and the continuous innovation in combination therapy programs have propelled China’s stroke thrombolysis research to the forefront of the global stage. China’s stroke thrombolytic therapy has undergone two decades of rapid development. This article reviews the transformative journey of thrombolytic therapy in Chinese clinical research on ischemic stroke over the past two decades from the perspective of a participant.

Key words: China; Thrombolytic therapy; Acute ischemic stroke

中图分类号:

董漪, 董强. 中国卒中临床研究中的溶栓治疗：20年的成就与发展方向[J]. 中国卒中杂志, 2025, 20(5): 549-554.

DONG Yi, DONG Qiang. Thrombolytic Therapy in Chinese Stroke Clinical Research: Achievements over the Past Two Decades and Future Directions[J]. Chinese Journal of Stroke, 2025, 20(5): 549-554.

参考文献

[1] 国家“九五”攻关课题协作组. 急性脑梗死六小时以内的静脉溶栓治疗[J]. 中华神经科杂志，2002，35（4）：210-213.
Cooperating Group for National 95’s Project. Intravenous thrombolysis with urokinase for acute cerebral infarctions[J]. Chin J Neurol，2002，35（4）：210-213.
[2] 王伊龙. 2005年溶栓、抗凝和抗血小板聚集治疗领域研究进展[J]. 中国卒中杂志，2006，1（3）：224-225.
WANG Y L. Research progress in thrombolysis，anticoagulation and antiplatelet therapy in 2005[J]. Chin J Stroke，2006，1（3）：224-225.
[3] 中国卒中学会. 缺血性卒中新再灌注治疗时代的海口宣言[J]. 中国卒中杂志，2023，18（12）：1465-1466.
Chinese Stroke Association. CSA declaration of next-generation reperfusion therapy for ischemic stroke[J]. Chin J Stroke，2023，18（12）：1465-1466.
[4] LI S Y，GU H Q，LI H，et al. Reteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2024，390（24）：2264-2273.
[5] XIONG Y Y，CAMPBELL B C V，SCHWAMM L H，et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy[J]. N Engl J Med，2024，391（3）：203-212.
[6] SAVER J L. Time is brain—quantified[J]. Stroke，2006，37（1）：263-266.
[7] KENNEDY J，HILL M D，RYCKBORST K J，et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence（FASTER）：a randomised controlled pilot trial[J]. Lancet Neurol，2007，6（11）：961-969.
[8] ZHAO J，LIU R Y. Stroke 1-2-0：a rapid response programme for stroke in China[J]. Lancet Neurol，2017，16（1）：27-28.
[9] CHENG X，HONG L，CHURILOV L，et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection：the umbrella phase Ⅱa CHABLIS-T randomised clinical trial[J]. Stroke Vasc Neurol，2024，9（5）：551-559.
[10] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[11] WANG L，DAI Y J，CUI Y，et al. Intravenous tenecteplase for acute ischemic stroke within 4.5-24 hours of onset（ROSE-TNK）：a phase 2，randomized，multicenter study[J]. J Stroke，2023，25（3）：371-377.
[12] ZHAO Z A，QIU J，LI W，et al. Intra-arterial tenecteplase during thrombectomy for acute stroke（BRETIS-TNK Ⅱ）：rationale and design[J]. Stroke Vasc Neurol，2024，9（1）：59-65.
[13] LI S Y，GU H Q，FENG B Y，et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset（PROST-2）：a phase 3，open-label，non-inferiority，randomised controlled trial[J]. Lancet Neurol，2025，24（1）：33-41.
[14] XIONG Y Y，HAO M J，PAN Y S，et al. Rationale and design of prourokinase in mild ischemic stroke（PUMICE）：a multicentre，prospective，randomised，open-label，blinded-endpoint controlled trial[J]. Stroke Vasc Neurol，2024，9（6）：715-722.
[15] SONG H Q，WANG Y，MA Q F，et al. Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset：a phase 3 randomized clinical trial[J/OL]. JAMA Netw Open，2023，6（7）：e2325415[2025-04-11]. https://doi.org/10.1001/jamanetworkopen.2023.25415.
[16] LI S Y，GU H Q，DAI H G，et al. Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours（RAISE）：rationale and design of a multicentre，prospective，randomised，open-label，blinded-endpoint，controlled phase 3 non-inferiority trial[J]. Stroke Vasc Neurol，2024，9（5）：568-573.
[17] ZHANG R R，WEI H，REN Y，et al. Outcomes and treatment complications of intravenous urokinase thrombolysis in acute ischemic stroke in China
[J/OL]. Front Neurol，2021，12：685454[2025-04-11]. https://doi.org/10.3389/fneur.2021.685454.
[18] WANG X H，LI X Q，XU Y M，et al. Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke：a nationwide prospective Chinese registry study[J]. Stroke Vasc Neurol，2021，6（4）：603-609.
[19] 饶明俐.《中国脑血管病防治指南》摘要（一）[J]. 中风与神经疾病杂志，2005，22（5）：388-393.
RAO M L. Chinese guidelines for cerebrovascular disease prevention and treatment：summary（Ⅰ）[J]. J Apoplexy and Nervous Diseases，2005，22（5）：388-393.
[20] ZHENG S X，ZHANG T，GU H Q，et al. Adherence to stroke care performance measures in different regions in China，2015—2019：evidence from the Chinese Stroke Center Alliance[J/OL]. Neurology，2022，99（16）：e1767-e1778[2025-04-11]. https://doi.org/10.1212/WNL.0000000000201024.
[21] XU J W，XIE Y N，FANG K，et al. Effect of the Shanghai Stroke Service System（4S）on the quality of stroke care and outcomes：a prospective quality improvement project[J]. Int J Stroke，2023，18（5）：599-606.
[22] CHEN Y，GUO X X，ZHONG W S，et al. Evaluation of a multilevel program to improve clinician adherence to management guidelines for acute ischemic stroke[J/OL]. JAMA Netw Open，2022，5（5）：e2210596[2025-04-11]. https://doi.org/10.1001/jamanetworkopen.2022.10596.
[23] LIU Z Y，GU H Q，WEI M P，et al. Comparison between healthcare quality in primary stroke centers and comprehensive stroke centers for acute stroke patients：evidence from the Chinese Stroke Center Alliance[J/OL]. Lancet Reg Health West Pac，2023，38：100863[2025-04-11]. https://doi.org/10.1016/j.lanwpc.2023.100863.
[24] 王建红，杨树，郭富强. 一个任重道远的话题：基层医院对急性缺血性卒中诊治指南的实践[J]. 中国卒中杂志，2018，13（6）：586-590.
WANG J H，YANG S，GUO F Q. Practice of acute ischemic stroke related guidelines in primary hospitals—a long way to go[J]. Chin J Stroke，2018，13（6）：586-590.
[25] 国家神经内科医疗质量控制中心. 2016神经内科医疗质量报告[Ｍ]. 北京：人民卫生出版社，2017.
National Center for Healthcare Quality Management in Neurology. 2016 report on quality of neurological medical care[M]. Beijing：People’s Medical Publishing House，2017.
[26] 上海市神经内科临床质量控制中心. 2016年国家医疗服务与质量安全报告：神经内科专业（上海地区分册）[M]. 上海：上海科学技术出版社，2017：45-48.
Shanghai Medical Quality Control Management Center in Neurology. 2016 national medical service and quality safety report：neurology specialty（Shanghai volume）[M]. Shanghai：Shanghai Scientific & Technical Publishers，2017：45-48.
[27] JIANG F，JIANG Y，ZHI H，et al. Artificial intelligence in healthcare：past，present and future[J]. Stroke Vasc Neurol，2017，2（4）：230-243.
[28] LI Z X，ZHANG X M，DING L L，et al. Rationale and design of the GOLDEN BRIDGE Ⅱ：a cluster-randomised multifaceted intervention trial of an artificial intelligence-based cerebrovascular disease clinical decision support system to improve stroke outcomes and care quality in China[J]. Stroke Vasc Neurol，2024，9（6）：723-729.
[29] RU X Y，WANG T H，ZHU L，et al. Using a clinical decision support system to improve anticoagulation in patients with nonvalve atrial fibrillation in China’s primary care settings：a feasibility study[J/OL]. Int J Clin Pract，2023：2136922[2025-04-11]. https://doi.org/10.1155/2023/2136922.